Pipeline

UbiVac and its collaborators are advancing a broad pipeline of immunotherapies—including next-generation cancer vaccines —now progressing through preclinical studies and clinical trials.

In a 2024 Phase Ib study, adding UbiVac’s DPV-001 vaccine to anti-PD-1 therapy tripled overall response rate, progression-free survival, and complete-response rate versus anti-PD-1 alone. Comprehensive immune-monitoring from this trial indicates that optimized combination regimens could push these outcomes even higher.

Data presented at the November 2024 Society for Immunotherapy of Cancer (SITC) meeting showed that the DPV-001 combination elicits T-cell responses capable of recognizing head-and-neck squamous-cell carcinoma, non-small-cell lung adenocarcinoma, melanoma, and renal-cell carcinoma. This cross-tumor reactivity points to targeting of shared, conserved tumor antigens, underscoring DPV-001’s potential as an off-the-shelf, broadly applicable cancer immunotherapy platform.